---
title: "What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings"
description: "Hims & Hers Health will announce its Q4 earnings on Monday after market close. Last quarter, it reported revenues of $599 million, a 49.2% year-on-year increase, but missed revenue guidance for the ne"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276525129.md"
published_at: "2026-02-22T03:07:25.000Z"
---

# What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings

> Hims & Hers Health will announce its Q4 earnings on Monday after market close. Last quarter, it reported revenues of $599 million, a 49.2% year-on-year increase, but missed revenue guidance for the next quarter. Analysts expect a 28.4% revenue growth this quarter, down from 95.1% last year. The company has added 32,000 customers, totaling 2.47 million. Hims & Hers Health's stock has dropped 46.7% recently, with an average analyst price target of $27.46 against a current price of $15.78.

Telehealth company Hims & Hers Health will be announcing earnings results this Monday after market close. Here’s what to look for.

Hims & Hers Health beat analysts’ revenue expectations last quarter, reporting revenues of $599 million, up 49.2% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but revenue guidance for next quarter missing analysts’ expectations significantly. It added 32,000 customers to reach a total of 2.47 million.

Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Hims & Hers Health’s revenue to grow 28.4% year on year, slowing from the 95.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health rarely misses Wall Street’s revenue estimates.

Looking at Hims & Hers Health’s peers in the healthcare technology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Tandem Diabetes delivered year-on-year revenue growth of 15%, beating analysts’ expectations by 4.9%, and Omnicell reported revenues up 2.3%, in line with consensus estimates. Tandem Diabetes traded up 32.7% following the results while Omnicell was down 20.6%.

Read our full analysis of Tandem Diabetes’s results here and Omnicell’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. Hims & Hers Health is down 46.7% during the same time and is heading into earnings with an average analyst price target of $27.46 (compared to the current share price of $15.78).

### Related Stocks

- [HIMY.US - Defiance Leveraged Long +Income HIMS ETF](https://longbridge.com/en/quote/HIMY.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMZ.US - Defiance Daily Target 2X Long HIMS ETF](https://longbridge.com/en/quote/HIMZ.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hims & Hers Health 的盈利前景 | Hims & Hers Health（紐約證券交易所代碼：HIMS）定於 2026 年 2 月 23 日公佈季度財報，分析師預測每股收益（EPS）為 0.03 美元。上個季度的業績低於預期 0.01 美元，導致股價下跌 3.6%。目前股價為 | [Link](https://longbridge.com/en/news/276467301.md) |
| Hims & Hers Health Inc 是在獲得市場支持還是在失去市場支持？ | Hims & Hers Health Inc (NYSE:HIMS) 的空頭頭寸增加了 6.24%，目前有 7676 萬股被賣空，佔可用股份的 41.71%。交易者平均需要 4.37 天來平倉這些頭寸。空頭頭寸的上升可能表明投資者的看跌情緒 | [Link](https://longbridge.com/en/news/276248796.md) |
| 在第四季度財報發佈之前，讓我們來看看誰持有 Hims & Hers 的股票（HIMS） | Hims & Hers Health (HIMS) 將於 2 月 23 日公佈 2025 年第四季度的財報。由於競爭、增長擔憂和法律問題，該股今年已下跌 51%。公眾和個人投資者持有 HIMS 46.9% 的股份，Vanguard 是最大的 | [Link](https://longbridge.com/en/news/276484443.md) |
| 未來展望：15 位分析師對休曼納的預測 | 在最新的季度中，15 位分析師對 Humana（紐約證券交易所代碼：HUM）給出了混合評級，平均 12 個月目標價為 221.8 美元，反映出 19.14% 的下降。主要分析師下調了他們的評級，其中 Wells Fargo 和 Goldma | [Link](https://longbridge.com/en/news/276258083.md) |
| 社區衞生系統第四季度的收入略低於分析師的預期 | 社區衞生系統第四季度的收入略低於分析師預期，報告為 31.1 億美元，而市場共識為 31.4 億美元。調整後的息税折舊攤銷前利潤（EBITDA）也未達到預期，錄得 3.95 億美元，預期為 3.9569 億美元。入院人數下降 6.6% 對收 | [Link](https://longbridge.com/en/news/276273944.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.